Pathology Peer Review&mdash;A Concept for Consideration TERRY S. PETERS
This article is based upon the author's individual opinion for improving the quality and accuracy of the pathology data provided to the Agency as part of Investigational New Drug Application (IND) and New Drug Application (NDA) submissions. The views of the author do not represent the official regulatory position of the Food and Drug Administration (FDA) . No official support or endorsement by the FDA is intended or should be inferred.
INTRODUCTION
Title 21, of the Code of Federal Regulations, Part 58 is a regulatory document commonly known as the good laboratory practice (GLP) regulations. The GLP regulations describe the practices for conducting nonclinical laboratory studies. These studies are &dquo;in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety. The term does not include studies utilizing human subjects or clinical studies or field trials in animals.&dquo; Most aspects of the conduct of nonclinical studies are addressed in these regulations. The GLPs, however, do not address all aspects of the histopathology phase of nonclinical studies. Although GLP inspections, done under the auspices of FDA's Bioresearch Monitoring Program, have included inspection of the pathology specimens considered to be raw data, they have not commonly included a pathologist's review of the histopathology data. The raw data for these purposes are defined as: the original study pathologist's narrative, gross necropsy results, histopathology slides, blocks, wet tissues, electron micrographs.
In the past, FDA has considered the pathology component to be part and parcel of the integrated submission not routinely subject to a specific scientific review by an independent or FDA pathologist. On rare occasions, individual pharmacology/toxicology reviewers or the Center for Drug Evaluation and Research's (CDER) Cancer Assessment Committee has requested the sponsor to submit histopathology slides for review by FDA pathologists. FDA has occasionally requested a National Toxicology Program (NTP) audit on material submitted in support of an NDA. The sponsor of the compound may reexamine the histopathology data generated in a study in response to queries from the review divisions. Upon occasion, these sponsor reviews have resulted in amendments to the data in an original submission.
The NTP, administered through the National Institutes of Environmental Health Sciences (NIEHS), has oversight responsibility of the major public carcinogenicity program in the world. NTP's scientists have tested more than 350 chemicals. Most of these substances were tested bv contract laboratories. Due to the interpretative nature of pathology and the variability of pathology terminology, morphologic diagnoses, and interpretation within the between laboratories, NIEHS decided that the NTP should conduct in-depth audits of all completed studies.
These audits include review of all clinical and anatomic pathology data (including slide review) and must be completed before a decision is made about the potential carcinogenicity of the compound. At the initiation of the audit program, NTP discovered and corrected avoidable errors in many studies. In a few studies, significant errors were identified that could not be corrected; these studies were considered inadequate and most were eventually repeated. The subsequent improvement in the quality of the data submitted to NTP is credited to the quality assurance (QA) program.
The determination of the carcinogenic potential of a compound is based upon a comparison of the incidence, tissue of origin, and latency period for development of various types of neoplasms between control and treated animals. Even differences of opinion or inconsistencies in terminology, morphologic diagnoses, and interpretation can significantly impact the toxicologic assessment of compound safety and carcinogenic risk to consumers.
The random review of the animal histopathology data submitted with NDAs has sometimes disclosed discrepancies that hindered interpretation of the safety of the compound. In the author's opinion, a consistent pathology quality assurance program in CDER, similar to that used by NTP, would benefit the scientific reviewers in evaluating histopathology data from chronic/carcinogenicity studies.
In 1987, the Environmental Protection Agency (EPA) issued Pesticide Registration Notice 87-10, which states in part: &dquo;The Agency also recommends the use of an independent pathology peer review system which would include the review of both normal and abnormal tissues.
If such a peer review provided the Agency with both the report of the original pathologist as well as that of the reviewing pathologist along with a consensus pathology report which resolved any differences of professional opinion between the original pathologist and the independent reviewing pathologist, then this would greatly increase the Agency's confidence in the pathology report portion of the study.&dquo; In August 1994, EPA published Pesticide Regulation Notice 94-5, which states: &dquo;The Agency is instituting a procedural requirement for any voluntary submissions of revised pathology diagnoses. This procedure will require a comprehensive peer review process, similar to the one used by the National Toxicology Program (NTP).&dquo;
In hearings on the GLP act, Senator Edward Kennedy stated:
&dquo;If the integrity of that data is questioned, then the whole regulatory process is questioned. If the data are proven false and misleading, then the regulatory decisions may be tragically wrong. Accurate science is the best protection the American people have from an unsafe and ineffective drug supply. &dquo;Inaccurate science, sloppy science, fraudulent science, these are the greatest threat to the health and safety of the American people. Whether the science is wrong because of incompetence of because of criminal negligence, is less important than the fact that it is wrong.&dquo;
Although the audit of the science of histopathology vas neither included in the U.S. GLP regulations, nor in he implementing guidelines, it seems obvious that it was he intent of Congress that all of the data bearing on the afety of a compound be scientifically accurate. It may )e appropriate for CDER to consider instituting a QA tudit of the histopathology data as part of the inspections )f pivotal (chronic/carcinogenicity) studies. Comments mdlor discussion concerning this subject would be help-&dquo;ul in formulating a position on pathology peer review.
The QA audit should ensure the accuracy of all aspects >f the histopathology phase of any pivotal (usually chronc/carcinogenicity studies) nonclinical study, including he microscopic diagnosis of individual lesions, reporting f histologic findings, and scientific interpretations of the iistopathologic data. Specific procedures should be implemented to ensure the consistency and accuracy of the 4istopathologic data, that the pathology report accurately summarizes the individual animal findings, and the interpretation presented in the study pathologist's narrative mammary accurately reflects the data.
The QA audit would consist of 2 stages. The extent of the histopathology QA audit could be dependent on the stage in the review process at which the audit is performed.
I. For studies that are being initially submitted as part of an IND/NDA, the pathology audit should consist of a formal histopathology QA peer review to ensure the consistency and accuracy of the histopathologic diagnoses and review of the pathology report to ensure that the data are accurately tabulated and that the interpretation reflects the data presented in the report. The pathology QA peer review should be conducted prior to submission with the NDA (ideally the review should be done just prior to finalizing the final study report).
II. For studies that have already been submitted to FDA in support of an IND/NDA, additional review of the histopathology findings by either an FDA pathologist or by the sponsor is sometimes needed to resolve questions raised by the pharmacology/toxicology reviewers. These reviews frequently result in new data, which may differ from the data originally submitted. The procedure for the submission of any revised histopathology data will include a comprehensive histopathology QA audit, including a QA peer review and potentially a pathology working group (PWG) review, similar to the process used by NTP
HISTOPATHOLOGY QA PEER REVIEW
The purpose of the histopathology QA peer review would be to audit the findings of the study pathologist and to increase the confidence of any subsequent reviewer that the report is an accurate reflection of the study events and findings. The review should be conducted by an independent pathologist, either an &dquo;in-house&dquo; sponsor pathologist (other than the study pathologist) or a consultant pathologist. The QA pathologist would review the original study pathologist's narrative report and tables with emphasis on inconsistencies in terminology or diagnostic criteria. This review, along with the information from threshold assessment, data from the in-life phase, and any other information about the compound will be used to select the tissues to be reexamined microscopically during the review. Individual animal necropsy and histopathology data from all animals in all groups will be reviewed and compared to determine that all gross lesions are addressed histologically. The extent of the review may vary from study to study but should generally include a review of diagnoses from treated and control animals, both normal and abnormal tissues. The review should, at a minimum, include reexamination of the following tissues: a. All slides from a random sample (usually IOalo) of animals from the control and high-dose groups for each sex. If evidence for substantial changes in the animal's longevity or for the induction of changes that might affect a neoplastic response is found, a random sample of the next lower dose would be examined. b. All proliferative lesions from all animals in all groups. This should include all neoplasms, hyperplasias, foci of cellular alteration, or other changes that are difficult to distinguish from neoplasia (e.g., focal gliosis). Usual findings in similar animals at similar ages (e.g., interstitial cell tumors in the testes and pituitary adenomas in aged Fischer 344 rats) should be verified but may not require as comprehensive a review. c. All tissues from all animals for which potential treatment-related effects are noted. In addition to target tissues, this may include the reexamination of tissues with unusual trends in the data from among groups or tissues for which the incidences of reported neoplasms vary from the laboratory's historical control data.
To complete the histopathology audit, the study pathologist and the QA pathologist should meet to resolve all differences noted between the original diagnoses and the QA pathologist's findings. The study pathologist and the QA pathologist will provide a consensus diagnosis for each difference noted during the peer review. This consensus should be reflected in the final histopathology data. No changes should be made to the original study pathologist's report, which is considered raw data.
The extent of the histopathology QA audit should be thoroughly described in the materials and methods sections of the final report, and the results of the audit should be reflected in the final diagnoses in the histopathology data. Documentation should include the tissues examined for each animal, the study pathologist's draft histopathologic diagnoses, the reviewing pathologist's diagnoses, a resolution of all diagnostic differences, and the actions taken to resolve each difference. This documentation should be presented on worksheets, which are considered raw data. These peer review worksheets should be main-tained in the study file to lend credulity to the peer review process and to assure that appropriate data changes were achieved.
If substantive diagnostic differences between the study pathologist and the reviewing pathologist were not resolved, these issues should be presented as part of the pathology narrative, along with a discussion on the impact of these differences on the study results and interpretation. If significant differences cannot be resolved between these pathologists, a PWG review should be convened to complete the resolution.
PWG REVIEW
Although the inability to resolve important differences between the study pathologist and the QA pathologist is unusual, the PWG review provides the best form of resolution. More commonly, the PWG review provides an independent assessment of the histopathologic data by a panel of experts to address specific questions concerning the study results. These questions generally arise during FDA's review of an IND/NDA.
Those persons involved in the PWG process include: study pathologist, the reviewing QA pathologist, PWG chairperson, and a panel of experts experienced in rodent pathology. The study and QA pathologists would be nonvoting members of the panel. The chairperson is responsible for the organization and conduct of the PWG. This allows the chairperson to understand thoroughly the problems to be resolved and to consider how best to present the materials to the PWG to resolve the specific issues in an unbiased, scientifically sound manner. It would be the responsibility of the PWG chairperson to anticipate and seek resolution of all potential problems in the pathology data that might impact on the overall interpretation of the study. The PWG review usually involves the evaluation of potential treatment-related changes in one or more target tissues.
For each target tissue being reviewed, the reviewing QA pathologist would reexamine all slides containing the tissue in all dose groups, as well as the controls. This should include slides previously classified by the study pathologist as within normal limits, in addition to those containing neoplasms, hyperplasias, hypertrophy, foci of cellular alteration, or other non-neoplastic lesions. The reviewing QA pathologist will assemble a set of all slides containing the target organs and lesions in question, which will include all discrepancies between the reviewing QA pathologist and the study pathologist. The PWG chairperson will use the set of slides and the reviewing pathologist's report to organize the PWG review of the differences and the target organs.
The PWG should examine all slides that contain substantive differences of opinion, as well as representative slides of target organ tissues containing the potential treatment-related changes in question. These slides will be organized by the PWG chairperson and presented to the panel in a coded fashion to preclude knowledge of dose groups or previously rendered diagnoses. The PWG will render a consensus diagnosis for each slide examined and verify treatment-related changes in target tissues. Each lesion will be discussed by the group, reexamined if necessary, and the final consensus opinion recorded. No changes to the consensus diagnoses should be made after the slides have been uncoded and the diagnoses tabulated for statistical analysis.
The PWG chairperson will assemble a report including a complete record of the PWG with a narrative summary, incidence tables, morphologic descriptions of the lesions examined, an evaluation of the study pathologist's assessment, comments on terminology, missed lesions, evaluation of the study pathologist's narrative report, evaluation of the histologic preparation, and the opinions of the PWG review.
The review division's scientists responsible for making regulatory decisions will consider the results of the PWG review and decide whether to accept the study without change from the original submission, to issue an incomplete letter requiring the sponsor to amend the tables and narrative to conform to the findings of the pathology audit, or to reject the study as inadequate to assess the safety or carcinogenic potential of the proposed product.
